DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% (DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%).
Dobutamine is a direct-acting inotropic agent primarily stimulating β1-adrenergic receptors, with mild β2 and α1 activity, increasing cardiac contractility and stroke volume.
| Metabolism | Hepatic metabolism via catechol-O-methyltransferase (COMT); also undergoes conjugation. |
| Excretion | Primarily renal (urinary) elimination; majority as metabolites (3-O-methyldobutamine and conjugates). Less than 5% excreted unchanged in urine. Minor biliary/fecal excretion. |
| Half-life | Terminal elimination half-life is approximately 2 minutes. Short half-life necessitates continuous intravenous infusion for sustained hemodynamic effect. |
| Protein binding | Approximately 25–30% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 0.2 L/kg, indicating limited distribution primarily to extracellular fluid and plasma volume. |
| Bioavailability | Oral bioavailability is essentially 0% due to extensive first-pass metabolism; therefore, not administered orally. Only intravenous administration is clinically relevant. |
| Onset of Action | Intravenous: 1–2 minutes; peak effect occurs within 10 minutes of starting infusion. |
| Duration of Action | Duration is short; hemodynamic effects diminish rapidly (within minutes) after discontinuation of infusion due to rapid redistribution and metabolism. |
IV continuous infusion: 2.5-20 mcg/kg/min titrated to hemodynamic response; start at 2.5-5 mcg/kg/min. Max dose: 40 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. GFR-based modifications: not applicable. |
| Liver impairment | No specific guidelines for hepatic impairment based on Child-Pugh score; use with caution due to reduced clearance. |
| Pediatric use | IV continuous infusion: 0.5-20 mcg/kg/min, titrate to effect. Initiate at 0.5-1 mcg/kg/min. |
| Geriatric use | Start at low end of dosing range (2.5 mcg/kg/min) and titrate slowly due to increased sensitivity and potential for tachycardia or hypertension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% (DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Due to short half-life and low oral bioavailability, systemic effects in infant are unlikely. Use with caution in breastfeeding mothers; consider risk-benefit. |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Dobutamine is used in pregnancy for maternal cardiac support; limited data suggest no major teratogenic effects in first trimester, but potential for uteroplacental insufficiency due to maternal hemodynamic changes. In second and third trimesters, use only if clearly needed; may cause fetal tachycardia or hypoglycemia due to maternal beta-adrenergic stimulation. |
■ FDA Black Box Warning
No FDA boxed warning specific to dobutamine; however, it may increase heart rate and exacerbate myocardial ischemia.
| Serious Effects |
Idiopathic hypertrophic subaortic stenosis, hypersensitivity to dobutamine or sulfites (present in some formulations).
| Precautions | May cause tachycardia, hypertension, hypotension, and ventricular arrhythmias. Monitor ECG, blood pressure, and cardiac output. Use caution in patients with atrial fibrillation or recent myocardial infarction. |
| Food/Dietary | No known food interactions. Dobutamine is administered intravenously; oral intake does not affect absorption or metabolism. Enteral feedings may continue unless contraindicated by the patient's condition. |
Loading safety data…
| Fetal Monitoring | Continuous maternal ECG, blood pressure, heart rate, and oxygen saturation. Monitor intrauterine fetal heart rate and uterine contractions if used in pregnancy. Assess maternal fluid status and signs of myocardial ischemia. Fetal monitoring for tachycardia or decelerations. |
| Fertility Effects | No human studies on fertility. Animal studies have not shown impaired fertility. Dobutamine is used short-term for hemodynamic support; no known long-term effects on reproductive function. |
| Clinical Pearls | Dobutamine is a direct-acting beta-1 agonist with minimal beta-2 and alpha effects. It increases myocardial contractility and cardiac output with mild chronotropic effects. Titrate to hemodynamic endpoints (e.g., cardiac index >2.5 L/min/m2). Tachyphylaxis can occur after 72 hours. Do not mix with sodium bicarbonate or alkaline solutions. Use with caution in atrial fibrillation (increases AV conduction), hypertension, and hypovolemia. Monitor for ectopic activity and hypotension. Contraindicated in idiopathic hypertrophic subaortic stenosis (IHSS). |
| Patient Advice | This medication is given intravenously to support your heart function. · You may feel your heart beating faster or irregularly; report palpitations or chest pain. · Report shortness of breath, dizziness, or leg swelling. · You will have frequent blood pressure and heart rate checks. · Do not stop or change the dose without medical advice. · Inform your healthcare provider of all other medications, including over-the-counter drugs. · This drug may cause anxiety, headache, or nausea. |